Shattuck Labs Inc (STTK)

$STTK - Shattuck Labs Inc. Common Stock - 10Q - Updated Risk Factors STTK flags new risks from FDA/government disruptions and broad macroeconomic threats, while removing detailed concerns on drug pricing scrutiny and healthcare reform impacts. #Biotechnology #HealthcarePolicy #FDADisruptions #MacroeconomicThreats #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/STTK/10-Q/2025-11-06

$STTK accumulation has been occurring between $1.90-$2

$STTK picked up another 5k @ $1.89 today, probably my last buy. long 25k

$STTK Shattuck Labs’ SL-325 Phase 1 Trial: A Key Development in Biopharmaceuticals TipRanks Clinical-Trials-Auto-Generated Newsdesk Oct 27, 2025, 04:16 PM Shattuck Labs’ SL-325 Phase 1 Trial: A Key Development in Biopharmaceuticals Shattuck Labs, Inc. (STTK +7.29% ▲ ) announced an update on their ongoing clinical study. Shattuck Labs, Inc. is conducting a Phase 1 clinical study titled ‘A Randomized, Double-Blind, Placebo-Controlled Single-Ascending Dose and Multiple-Ascending Dose Phase 1 Study of SL-325 in Healthy Volunteers.’ The study aims to evaluate the safety and tolerability of SL-325, a DR3 blocking antibody, in healthy individuals. This research is significant as it represents the first human trial of SL-325, potentially paving the way for future therapeutic applications. The intervention being tested is SL-325, a biological treatment designed to block DR3, with the goal of assessing its safety profile. Participants in the study receive either single or multiple doses of SL-325 or a placebo. The study is interventional, with a randomized and sequential design. It employs a double-blind approach, meaning both participants and investigators are unaware of who receives the treatment or placebo. The primary purpose is to evaluate treatment effects. The study began on August 28, 2025, with recruitment currently ongoing. The primary completion and estimated study completion dates are yet to be announced. The last update was submitted on the same day as the study’s initiation. This update could influence Shattuck Labs’ stock performance, as positive results may boost investor confidence and interest. The study’s progress is crucial for stakeholders, with potential implications for competitors in the biopharmaceutical industry. The study is ongoing, with further details available on the ClinicalTrials portal.

$TLT $HYFT $GDXD $UVIX $STTK Current holdings Options TLT $100 Call 1/15/2027 • 101 buys Stocks STTK 15,000 Shares HYFT 100,000 Shares TLT 1,110 Shares UVIX 500 Shares GDXD 1,500 Shares

$STTK The insider buyer in Sept. privately and through her orbimed advisors llc Dr. Ashiya is a General Partner at OrbiMed where she has been involved in a number of the firm’s private and public company investments. Prior to joining OrbiMed in 2010, Mona covered the biotechnology industry as a member of J.P. Morgan’s biotechnology equity research team. Her previous experience includes positions at the Global Alliance for TB Drug Development and the Harvard Business School. Mona has also published scientific articles in various peer reviewed journals. She earned a B.A. degree from the University of California at Berkeley, a Ph.D. in Cellular, Molecular, and Developmental Biology from the University of Pittsburgh, and was a post-doctoral fellow at the Dana Farber Cancer Institute.

$STTK Oct 2025: Insiders made 2 informative buys of 13M shares of STTK in the last three months. This is not investment advice

$STTK I think this one wants to tell us a story soon..... Consolidating the last 1 1/2 months after a 100+% rapid rise and this Director Orbimed Advisors Llc Informative Buy Shares bought on the open market 6,306,127 $5,423,269 Sep 2, 2025 Director Mona Ashiya Informative Buy Shares bought on the open market 6,306,127 $5,423,269 Sep 2, 2025

$STTK nothing to see here. Just casually up 17%! 😉

$STTK small caps are hurting except...